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Abstract The neonatal Fc receptor (FcRn), also known as
the Brambell receptor and encoded by Fcgrt, is a MHC
class I like molecule that functions to protect IgG and
albumin from catabolism, mediates transport of IgG across
epithelial cells, and is involved in antigen presentation by
professional antigen presenting cells. Its function is evident
in early life in the transport of IgG from mother to fetus and
neonate for passive immunity and later in the development
of adaptive immunity and other functions throughout life.
The unique ability of this receptor to prolong the half-life of
IgG and albumin has guided engineering of novel thera-
peutics. Here, we aim to summarize the basic understanding
of FcRn biology, its functions in various organs, and the
therapeutic design of antibody- and albumin-based thera-
peutics in light of their interactions with FcRn.
Keywords FcRn.Fcgrt.Brambell.IgG.Fc.albumin.
transcytosis.transport.recycling
Introduction
Decades before the identification of neonatal Fc receptor
(FcRn) as the receptor that transports IgG from mother to
offspring, early experiments revealed passive transfer of
immunity via gamma-globulin. Francis William Rogers
Brambell (1901–1970) was an Irish-born zoology professor
who made significant contributions to these observations
and subsequently hypothesized the existence of a receptor
that can mediate the transfer of maternal gamma-globulin
from mother to infant as well as the protection of gamma-
globulin from catabolism [1, 2]. Later studies by Richard
Rodewald's group provided biochemical evidence of IgG
transport at the neonatal rat intestinal epithelium with pH
binding dependency [3]. This finally led Neil Simister and
Keith Mostov to purify and sequence a Fc receptor from
the intestine of an 11-day-old rat (hence the name neonatal
Fc receptor) that was associated with beta (β)-2-micro-
globulin and exhibited structural similarity to MHC class I
molecules [4].
FcRn Structure and Ligand Binding Characteristics
Similar to MHC class I, FcRn structure consists of three
extracellular alpha (α) domains, a single pass transmem-
brane domain, and a short cytoplasmic tail of approximately
44 amino acids. Crystal structural resolution by Pam
Bjorkman's group, who had previously resolved the crystal
structure for MHC I, showed that the α1 and α2 domain
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where peptide termini anchors in MHC class I are blocked
in FcRn by an arginine side chain and another by a proline
residue in the α2 helix region [5]. Two FcRn molecules
bind to a single IgG with a 2:1 stoichiometry, and the
binding occurs at pH 6.0–6.5 with minimal structural
conformation change and not at pH 7.5 [5, 6]. The
critical binding site at acid pH in the IgG Fc domain
resides within a pair of histidines that occur in the α3
domain [7]. Rat FcRn and IgG binding studies have shown
that the FcRn contact sites for IgG involve Aspartic acid
137, an N-glycan moiety within the α2 domain, and the N
terminus of β2m [8].
The observation that staphylococcal protein A blocks
FcRn and IgG binding helped to identify the CH2–CH3
domain interface as a critical site of FcRn–IgG interactions.
Site-directed mutagenesis studies have proven that the
critical binding sites in the Fc domain of IgG for FcRn
are Histidine 310, Histidine 435, and Isoleucine 253 and to
a lesser extent Histidine 433 and Tyrosine 436 [9, 10]. At
acid pH, the protonated histidine residues on IgG form a
salt bridge with the FcRn α2 domain at Glutamic acid 117,
Glutamic acid 132, and/or Glutamic acid 135 and Aspartic
acid 137.
Binding Site of Albumin
Although a putative albumin receptor was also hypothe-
sized by Schultze and Heremans in 1966, it was not until
2003 when Clark Andersen's group demonstrated a bio-
chemical association between FcRn and albumin [11, 12].
FcRn also protects albumin from catabolism and thus in
humans the endogenous albumin half-life is approximately
19 days, while in rodents, it is 1.5–2.5 days. FcRn in the
liver is the critical site that maintains albumin concentration
homeostasis by producing the same quantity as is degraded
systemically [13]. FcRn binds albumin with a 1:1 stoichi-
ometry. Similar to the pH dependency of FcRn–IgG
interactions, FcRn and albumin also bind together at acidic
pH but not at neutral pH. The contact site of FcRn also
involves a histidine residue (H166) within the α3 domain
but located on the opposite structural face of FcRn from
that which is involved in contacting IgG [14, 15]. The FcRn
contact site on albumin resides somewhere within the last
third of its three major structural domains. It is still not
known whether a single FcRn can simultaneously bind and
transport both IgG and albumin in physiologic conditions.
Also, the crystal structure FcRn bound to albumin has yet
to be resolved. Nonetheless, genetic deficiency of FcRn in
genetically engineered animal models has clearly shown
that such mice are both hypoalbuminemic and hypogam-
maglobulinemic [13, 16].
FcRn Structural Comparisons Between Species
The rat and mouse FcRn peptide sequences are 98%
identical and are encoded in chromosome 7, outside the
MHC class I locus in chromosome 20 and 17, for rat and
mouse, respectively. Human FcRn shares only 65% amino
acid sequence similarity with rat FcRn. Human FcRn is
encoded in chromosome 19, also outside of the MHC class
I locus on chromosome 6. The molecular weight of human
(h) FcRn is approximately 42–44 kDa with a single N-
glycan moiety, as opposed to rat FcRn which has three
additional N-glycans that account for its molecular weight
of 48–52 kDa. This structural dissimilarity may explain the
absence of hFcRn dimer formation, in the absence of IgG,
in crystal structure studies. Perhaps it is the lack of the
additional N-glycan moieties within the α2 domain that
participate in the formation of dimer stability through a
“carbohydrate handshake” as shown by X-ray crystallo-
graphic studies [17]. Another major difference between
human and rodent FcRn involves the cross-species IgG
binding. Rodent FcRn is known to be “promiscuous” in its
ability to bind various species of IgG, while hFcRn can
only bind to a limited species (human, rabbit, and bovine)
[18]. “Murinizaton” by site-directed mutagenesis of hFcRn
at residues 137 and 121–132 within the α2 domain was
shown to allow binding to mouse IgG, thus helping to
explain this cross-species IgG binding capability of rodent
FcRn [19]. Although one of the N-glycans resides within
the above-mutated site, it probably does not contribute to
cross-species IgG binding, since “rodentization” of hFcRn
by addition of N-glycans through site-directed mutagenesis
failed to enhance binding to rodent IgG [20]. Although
hFcRn cannot bind rodent IgG, recent findings have shown
that hFcRn can bind rodent albumin, but rodent FcRn
cannot bind human albumin [21]. Thus, the half-life of
human albumin in rat is only 15 h [22].
FcRn has also been cloned from other species, such as
cow, possum, sheep, water buffalo, and camel [23]. The
major structural similarities between possum, sheep, and
cow include a single N-glycan moiety and a cytoplasmic
tail that is ten amino acids shorter than that of the rodent
counterpart. To date, cross-species FcRn–β2m binding has
been suggested to occur with bovine FcRn and mouse β2m
when the bovine FcRn transgene was expressed in mice and
was found to be functional [24].
Intracellular Trafficking of FcRn
β2m association with FcRn is required for proper folding of
FcRn before exiting the endoplasmic reticulum (ER), and
failure of such an association results in the formation of
disulfide-bonded oligomers that accumulate in the ER [25].
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also requires association with β2m [26]. Prior to binding
with β2m, FcRn assembly involves association with
calnexin and subsequently ERp57 which assist in the
formation of the disulfide bond [27]. Calreticulin is also
involved in the maturation of the FcRn–β2m complex in
the ER [27].
FcRn expression in many different polarized epithelia in
vitro systems that model the kidney, lung, placenta, and
intestines has shown that FcRn expression endows upon the
cell the ability to transcytose IgG bidirectionally [26, 28–
31]. The uptake of IgG by FcRn requires an acid
environment that can occur within the intestinal lumen
especially during neonatal life or in acidified endosomes. In
the neonatal rat proximal intestine, a luminal pH of 6.0–6.5
favors FcRn binding to IgG in milk for apical uptake and
subsequent endocytosis and transcytosis to the contralateral
basal surface where the pH of the circulation is approxi-
mately 7.5 which allows ligand dissociation. In the absence
of an acidic pH, IgG uptake likely occurs by fluid-phase
pinocytosis and subsequent binding to FcRn after acidifi-
cation of the endosome. Whether FcRn undergoes recycling
or transcytosis is still under active investigation. It is known
that transcytosis involves actin motor myosin Vb and
GTPase Rab25. Rab11a has also been found to be
dispensible for transcytosis but regulates basolateral mem-
brane recycling [32]. Exocytosis involves Rab11 which is
important for endosomal fusion with the plasma membrane
[33]. Recent electron microscopy of FcRn trafficking in rat
intestine has revealed that both endocytic and exocytic
processes are associated with clathrin [34].
Regulation of intracellular trafficking in polarized
epithelial cells has mostly been studied using kidney cell
lines, such as MDCK or IMCD cells, which are grown as
monolayers on the transwell system. As mentioned previ-
ously, β2m association is critical to effective function of
FcRn [26]. The cytoplasmic tail has been demonstrated by
several studies to play a critical role in basolateral
membrane targeting, as well as endocytosis and trans-
cytosis. hFcRn without a cytoplasmic tail or one that
contains mutations in the calmodulin binding site results in
redistribution of hFcRn from the basolateral to the apical
surface and reduced IgG transport [35, 36]. rFcRn without
the cytoplasmic tail or with a point mutation at the
phosphorylation site serine-313 results in decreased
apical-to-basolateral IgG transport [37]. Mutation of the
tryptophan and dileucine motif in the cytoplasmic tail also
results in increased apical membrane expression [38].
When the rFcRn cytoplasmic tail was attached to the
FcγRII receptor, this mutant receptor could transcytose
across MDCK cells in both directions [39]. The regulation
of apical membrane targeting likely involves N-glycans. In
a study where hFcRn was “rodentized” by expression of
additional N-glycans to resemble that of rFcRn, the mutant
hFcRn redistributed to the apical membrane, similar to that
of wild-type rFcRn. The mutant hFcRn containing addi-
tional N-glycans also reversed the direction of predominant
IgG transport to an apical-to-basolateral direction similar to
that of wild-type rFcRn [20].
The pathway of FcRn trafficking is also determined by
the valency of the ligand. In dendritic cells, FcRn bound to
large multimeric immune complexes is routed to a LAMP1
+
compartment while monomeric IgG is recycled back to the
cell surface [40]. This is believed to facilitate antigen
processing before antigen presentation in dendritic cells
which are known to express FcRn [41]. In another study,
wild-type Fc with two FcRn-binding sites was more
efficiently transported and less likely to be destined for
lysosomal degradation than mutant Fc with a single FcRn-
binding site [42].
Regulation of FcRn Expression
Studies of the promoter regions (comparing neonatal
intestinal epithelium and NIH 3T3 cells) have shown that
different transcription factors can regulate the expression of
FcRn at different developmental stages and tissue types
consistent with the well-known developmental regulation of
FcRn in rodent intestinal epithelia [43]. Upregulation of
FcRn expression in intestinal epithelial cells, macrophage-
like THP-1, and primary human monocytes can be induced
by TNF-α and IL-1β, which are known to be elevated
during inflammation [44]. Conversely, INF-γ was found to
down-regulate FcRn expression [45].
FcRn expression in the neonatal intestinal epithelium of
rat can also be subjected to hormonal control, and thus may
explain the exceedingly high expression levels through
early life. Cortisol and thyroxine can suppress FcRn
expression in neonatal rat intestinal epithelium as well as
inhibit IgG binding [46, 47]. Meanwhile, a different study
showed that dexamethasone stimulation decreases FcRn
mRNA in rat alveolar epithelial cells [31].
Intestinal Expression and Function of FcRn
FcRn expression in rat intestine is only detectable up to
19 days after birth, which coincides with weaning, and the
level of expression decreases distal to the proximal
duodenum. The acid pH at the proximal duodenum
likely facilitates the uptake of IgG. Recent studies by
Bjorkman and colleagues have tracked the intracellular
pathways associated with individual nanogold-labeled Fc
after uptake from the neonatal rat intestinal lumen and
have shown the existence of a complex network of
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through clathrin-coated pits as important to intracellular
pathway of transcytosis [34].
Although the expression of FcRn in the intestine of adult
mice is nearly undetectable, induction has been observed
upon intraperitoneal immunization with Cry1Ac protoxin
from Bacillus thurigiensis but at levels less than that
typically observed during neonatal life [48]. This is
consistent with an increasing body of data on an important
functional role of FcRn in intestinal epithelia during adult
life (Table I).
In humans, FcRn is detected in both fetal and adult
intestinesandcanmediatebidirectionaltranscytosisacrossthe
intestinal epithelium both in vitro and in vivo [28, 49–51].
FcRn in the intestine and other mucosal tissues therefore
continues to play a significant role beyond the neonatal
period, especially in immune surveillance and adaptive
immunity. Using mice that were humanized to express
human FcRn under the control of its endogenous promoter
and β2m as transgenes within intestinal epithelial cells, FcRn
at the intestinal epithelium was found to deliver IgG to the
luminal surface where it bound to a cognate antigen before
returning the complex back to the lamina propria for
processing and presentation by dendritic cells to CD4
+ T
cells [51]. In a murine model of intestinal infection using
Citrobacter rodentium, which only infects intestinal epithe-
lial cells and is dependent upon IgG for eradication, FcRn
within the intestinal epithelium was shown to be essential in
directing C. rodentium-associated antigens within the epithe-
lium to regional lymph nodes for initiation of an adaptive
immune response [52, 53]. In the absence of FcRn, C.
rodentium elimination was slowed. These observations also
help to explain the role of the high levels of antibacterial IgG
that are observed within intestinal tissues and the lumen in
inflammatory bowel disease (IBD). Using a murine model of
colitis, antibacterial IgG was shown to drive colitis and was
dependent upon FcRn expression in antigen presenting cells
[54]. These studies thus show an important role for FcRn in
mediating IgG-dependent anti-infective immunity and po-
tentially autoimmunity in immune-mediated disorders such
as IBD. Such observations have important implications for
adaptive immunity in general.
Expression and Function of FcRn in Mammary Gland
The mammary gland expresses various Ig receptors,
including FcRn, pIgR, and CD23, for the transport of
IgG, IgA, and IgE, respectively. In sheep, the major
concentrations of Ig in colostrum in descending order are
IgG1, IgA, IgE, IgM, and IgG2. In milk, the concentrations
in descending order are IgA, IgM, IgE, IgG1, and IgG2
[55]. The concentration of IgG in human colostrum is 1 g/L,
while milk only contains 50 mg/L. On the other hand, the IgA
concentration in human milk is 32 g/L.
FcRn has been found to be expressed in the mammary
gland of human, mouse, cow, brushtail possum, sheep,
swine, and camel [23]. In humans, FcRn is detected in the
mammary gland endothelial cells rather than the epithelial
cells [56]. In camels and water buffalo, immunohistochem-
istry has demonstrated labeling within the acini and ducts
[57, 58]. FcRn is also detected in tumor tissues such as
ductal, lobular, and medullary carcinoma, as well as
metastatic epithelial cells in the lymph node [56]. It is also
detected in the histiocytes residing within the interstitium in
association with breast cancer.
It is believed that FcRn in the mammary gland likely
recycles IgG (to retain IgG in circulation) rather than
promoting transport from circulation to milk. In normal
lactating mice, the concentration of IgG in milk is less than
that of serum. In β2m-deficient mice, the concentration of
IgG in milk was observed to be 20-fold less than that of
serum [59]. Studies comparing transfer of Fc fragments and
IgG with different affinities to FcRn revealed an inverse
relationship between binding affinity and concentration in
milk [60]. When a bovine FcRn transgene was expressed in
the mammary gland of mouse, there was no increase in the
milk of the infused mouse or bovine IgG which is
consistent with this notion [24].
The expression levels of FcRn in the mammary gland
can shift during lactation [61]. In cow and sheep, there
appears to be a shift in the expression of FcRn to the apical
membrane location after parturition [62, 63].
The clinical benefit of the long-observed transfer of
passive immunity has recently been demonstrated using a
murine model of asthma in which the transfer of maternal
IgG1 from milk to the infant was shown to prevent
allergen-specific airway disease [64–66]. Complete protec-
tion of offspring from antigen-specific allergic airway
inflammation was observed.
Expression and Function of FcRn in Placenta
The transfer of passive immunity is predominantly postna-
tal in rodent but in utero during gestation in humans and
rabbits [67]. In humans, maternal IgG in the fetal
circulation increases from the early second trimester to
term. IgG1 and IgG4 have found to be most efficiently
transport, while IgG2 is the least. The transfer of IgG is
believed to be due to FcRn in the human syncytiotropho-
blast and the fetal intestine [49, 68]. In mouse, FcRn is
expressed in the mouse yolk sac endoderm but not the
chorioallantoic placenta, and it is likely the sole IgG
transporter from mother to fetus [69]. Using BeWo cells
(a human trophoblast-derived cell line that expresses FcRn)
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port and recycling of IgG have been observed [29, 70].
Although FcγRIIb is expressed in the human placental
villous endothelium and yolk sac vasculature and previous-
ly believed to also transport IgG across the villous
endothelium, recent studies comparing FcγRIIb-deficient
mice and wild-type mice have revealed that FcγRIIb does
not mediate IgG transport in the mouse yolk sac [71].
Placental transfer of IgG from mother to fetus can also
be used to transport therapeutic recombinant Fc fusion
proteins in utero. When a β-glucuronidase (GUS)-Fc fusion
protein was infused into the pregnant mouse in a murine
model of GUS deficiency, the offsprings were found to
have reduced manifestation of excessive lysosomal storage
in the involved organs [72]. Conversely, potentially
pathogenic antibodies may also be transferred via the
placenta. In a murine model of fetal and neonatal immune
thrombocytopenia (FNIT), where the transfer of pathogenic
maternal antibody results in the destruction of fetal/neonate
platelets, FcRn was found to be critical for this pathologic
condition to occur [73]. The transport of the pathogenic IgG
was likely facilitated by placental FcRn, since treatment
with an anti-FcRn antibody or intravenous immunoglobulin
(IVIg) was found to prevent FNIT. Other than pathogenic
antibodies, teratogens or peptide inhibitors of FcRn can
also block the transport of IgG in the placenta, leading to
placental necrosis and/or disruption of embryo development
[74]. However, such inhibitors may serve as a method of
preventing transfer of pathogenic antibodies from the
maternal circulation.
Expression and Function of FcRn in Lung
FcRn expression in the lung has been exploited as an
endogenous vehicle for delivery of therapeutic Fc fusion
proteins and in so doing revealed the presence of
physiologic transport of IgG in adult lung by FcRn [75].
FcRn is expressed by bronchial epithelial cells of adult
human, non-human primate, rat, mouse, and cow, wherein
it can mediate transport of IgG. Consistent with this,
significant quantities of IgG can be observed in pulmonary
secretions [76]. FcRn is also detected at high levels in
tracheal epithelial cells [77, 78]. This likely explains the
efficacy of Fc fusion protein delivery when inhalation is
directed to the upper airways in non-human primate
experiments and human clinical trials [79, 80]. Consistent
with this, mutation of the FcRn-binding site within the Fc
domain of the chimerized IgG fusion disables such
transport [81]. Although it is not detectable in alveolar
cells of humans and non-human primates, rat alveolar
epithelial cell monolayer studies have demonstrated expres-
sion of FcRn at this site that can mediate bidirectional
transport of IgG and with a predominant apical-to-basal
direction [31, 77, 81].
Expression and Function of FcRn in Hematopoietic
Cells
FcRn has been observed to be expressed in human
monocyte, macrophage, dendritic cells, splenic B cells,
and monocytic cell lines such as U937 and THP-1 [41, 82].
FcRn expression levels in these cell lines has been found to
be increased by exposure to CpG, LPS, and TNF-α, and
decreased with inhibition of NF-κB[ 44]. FcRn is also
expressed in mouse hematopoietic cells, and within this cell
type, it has been shown to be involved in IgG homeostasis
together with endothelial cells [40, 41, 82, 83].
In dendritic cells, FcRn sorts multimeric IgG-containing
immune complexes to intracellular compartments associat-
ed with antigen processing and ultimately degradation such
that immune complexes exhibit diminished clearance in
vivo in the absence of FcRn function [40, 84]. Consistent
with this, FcRn in human and mouse dendritic cells plays a
critical role in MHC class II-restricted antigen presentation
[40]. FcRn in dendritic cells can also mediate MHC class I-
restricted cross-presentation in the setting of chronic
inflammation (K.B. and R.S.B. unpublished observations).
Dendritic cells may also be involved in tolerance induction
since oral administration of anti-CD3 antibody has been
found to be effective in prevention and treatment of
autoimmune diabetes and encephalomyelitis in mice [85].
In neutrophils, FcRn can facilitate the uptake of bacteria
opsonized by antigen-specific IgG and deliver it to
phagolysosomes [86].
Expression and Function of FcRn in Kidney
Consistent with studies of kidney cell lines, bidirectional
transport of IgG in primary human renal proximal tubular
epithelium had been observed [87]. FcRn is expressed in
the podocyte and proximal tubule, but not the mesangial
cell, parietal epithelial cells, interstitium, medulla, or distal
tubular cells [88, 89]. FcRn in podocytes reabsorb IgG from
the glomerular basement membrane which prevents depo-
sition of immune complexes that might lead to glomerular
diseases. This conclusion stems from the observation that
FcRn-deficient mice exhibit accumulation of IgG in the
glomerular basement membrane and delayed IgG clearance
from the kidney. Excess IgG filtered by glomeruli can also
be reabsorbed downstream by FcRn in the proximal
tubules.
In a different study in which kidney transplants were
performed between FcRn-deficient and wild-type mice,
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urinary loss but promotes IgG secretion [90]. Through IgG
and albumin localization, FcRn was shown to be expressed
in the podocytes, the proximal tubular epithelial cells, and
the vascular endothelium of the kidney. It was proposed that
albumin was filtered through the glomerulus and later
reabsorbed at the level of the proximal tubular epithelial cell.
Similarly, it was proposed that IgG is reabsorbed by the
podocyteandthatFcRnwithinthe renal vascularendothelium
removes IgG from the circulation into the interstitium for
subsequent uptake by proximal tubular epithelial cells for
transcytosis back to the urine to provide immunity against
infection. Both studies thus concur that FcRn within podo-
cytes functions to reabsorb IgG, but FcRn in the renal system
outside of the glomeruli may be more complex in the need to
balance immunity and salvage protein. Adding to the
complexity, other proposed albumin-binding proteins at the
proximal tubular epithelial cell-associated brush border, such
as megalin and cubilin, may also be involved in albumin
regulation in the urinary system [91].
Expression and Function of FcRn in Liver
FcRn expression in the liver had been demonstrated at both
canalicular and sinusoidal membranes, and it is functional
in IgG binding [92, 93]. The liver is the site of albumin
synthesis, and FcRn in the liver regulates albumin homeo-
stasis [13]. Previous attempts to understand the role of
FcRn function in the liver using β2m-deficient mice and
radio-isotope-labeled IgG and albumin failed to demon-
strate transcellular transport through the hepatocyte and
supported a role for FcRn in the liver for the protection of
IgG from catabolism [94]. Surprisingly, the same study also
did not show differences in the infused serum isotope-
labeled albumin levels between β2m-deficient and wild-
type mice raising concerns over the data presented.
However, this may be a result of oversaturation of the
infused albumin or inadvertent structural changes caused by
isotope labeling.
Other than protection from catabolism, FcRn in the liver
can prevent IgG and albumin loss through the biliary
system. Our unpublished data has shown that the bile of
FcRn-deficient mice exhibits elevated levels of endogenous
IgG and albumin compared to that of the wild-type
counterparts. Our in vitro studies using monolayer cells
grown on a transwell system have shown that FcRn can
also mediate bidirectional transport of albumin across
polarized epithelia (MDCK II cells) as well as basolateral
recycling. This suggests that FcRn salvages IgG and
albumin from loss in the bile, either through basal
membrane recycling and/or transport of IgG and albumin
from the canalicular-to-sinusoidal membrane.
Expression and Function of FcRn in Brain
FcRn expression in the br a i nh a sb e e nf o u n dt ob e
located within the capillary endothelium and choroid
plexus epithelium using confocal microscopy [95]. FcRn,
along with other immune regulated genes, is also found to
be upregulated in brain tumors, such as pilocytic astrocy-
tomas, grade II astrocytomas, and oligodendrogliomas
[96]. However, the role of FcRn in these tumors is still
unclear.
FcRn at the blood brain barrier (BBB) is hypothesized to
mediate the efflux of IgG from brain to blood in a process
of “reverse transcytosis”. Murine models of Alzheimer's
disease have shown that FcRn within the BBB is involved
in the removal of amyloid beta-peptide specific IgG
complexes from the brain of older mice, and thus plays a
role in Alzheimer's disease immunotherapy [97]. However,
a recent study did not find FcRn as the major factor for the
low exposure of IgG in the brain [98]. Therefore, the
function of FcRn in the BBB and the brain will require
further investigation.
Expression and Function of FcRn in Eye
FcRn in the eye has been localized to various ocular tissues,
including corneal epithelium and endothelium, lens epithe-
lium, retinal blood vessel, conjunctiva lymphatic vessel,
nonpigmented ciliary epithelium, ciliary blood vessel, iris
blood vessel, and optic nerve vessel. FcRn was not detected
in the retinal pigment epithelium and the choroid [99].
Murine studies of intravitreal injection of IgG suggest that
ocular FcRn removes IgG across the blood–retina barrier
into the systemic circulation similar to the process of
reverse transcytosis described for the BBB [100]. Whether
ocular FcRn is also involved in the common ophthalmic
manifestations associated with various autoimmune dis-
eases still requires investigation.
Expression and Function of FcRn in Skin
FcRn has been found to be expressed in human epidermal
keratinocytes, melanocytes, hair follicles, and sebaceous
glands [101, 102]. The specific function in these cells has
yet to be studied. In rodent models of bullous pemphigoid,
pemphigus foliaceus, and pemphigus vulgaris, the disease
was ameliorated in FcRn-deficient mice or following
administration of high-dose IgG [103]. The therapeutic
effect likely reflects increased overall degradation of
pathogenic IgG antibodies. Whether FcRn in the skin also
directly contributes to the development of autoimmune skin
blistering diseases is still unknown.
J Clin Immunol (2010) 30:777–789 783Disease Associations with FcRn
Although animal models have shown that FcRn is involved
in colitis, autoimmune skin blistering diseases, and transfer
of immunity in asthma, to date, a specific human disease
that is attributable to an “FcRn disorder” has yet to be
found. A single report of FcRn deficiency was observed in
two siblings of a consanguineous marriage who were
recorded to have significantly decreased levels of IgG and
albumin levels in the blood [104]. Using archived samples,
an analysis revealed normal FcRn DNA sequence but a
single nucleotide transversion at the signal sequence of the
β2m gene that mutated a conserved alanine to proline. The
resulting β2m and HLA concentration decreased to <1% of
normal. The only reported human population genetic study
so far involved 404 Han Chinese subjects with and without
lupus nephritis. Analysis of the variable number of tandem
repeat polymorphisms within the FcRn gene promoter did
not show any differences [105].
Therapeutic Implications of FcRn Function
Engineering IgG and albumin conjugates for prolonged or
decreased half-life has been the cornerstone of many types
of therapeutic design. The transcytosis function of FcRn in
mucosal surfaces and placenta can also allow for a novel
mode of drug delivery. Optimizing the interactions between
IgG and FcRn is crucial in maximizing therapeutic efficacy
while avoiding potential toxic effects.
IgG-Based Therapeutics
Recombinant therapeutics genetically engineered to contain
IgG fragments with the CH2–CH3 domain can have
significantly prolonged half-life due to protection through
catabolism by FcRn binding. This also has the benefit of
decreasing the frequency of administration. Methods to
increase IgG binding to FcRn have been performed by
mutating IgG at various amino acid residues: Threonine
250, Methione 252, Serine 254, Threonine 256, Threonine
307, Glutamic acid 380, Methione 428, Histidine 433, and
Asparagine 434 [106]. However, increased binding affin-
ity does not appear to be proportional to the half-life
extension. For example, when comparing variants of
Herceptin (ERBB2-specific human IgG1 by Genentech)
antibody with a threefold increase in FcRn binding at
acidic pH and another variant with a 12-fold increased
binding at acidic pH and also enhanced binding at neutral
pH, both antibodies exhibited similar half-lives when
tested in a humanized FcRn transgenic mouse model
[107]. It has been hypothesized that increasing binding at
neutral pH prevents IgG release and may instead promote
degradation.
Therapeutics can also be engineered to have decreased
binding wherein short half-life is desirable to avoid toxic
adverse effects. For example, radiographic diagnostic
imaging and toxin-conjugated products (i.e., for cancer
treatment) would not require prolonged circulation in the
bloodstream [108, 109].
Elimination of pathogenic antibodies in autoimmune
diseases can be achieved by plasmapheresis, corticosteroid
administration, or B cell depletion. An alternative method
of elimination involves direct inhibition of FcRn and its
interactions with IgG to promote catabolism of native
pathogenic antibodies. This has been traditionally achieved
by administration of IVIg, which is believed to compete
with FcRn binding, thus resulting in accelerated degrada-
tion of endogenous pathogenic IgG antibodies left unbound
to FcRn. Treatment with IVIg in murine models of
myasthenia gravis, bullous pemphigoid, idiopathic throm-
bocytopenia, and autoimmune arthritis confirmed the
benefit of increasing pathogenic IgG degradation as a
means to block the immune-mediated disorder, and it
appears to be independent of FcγRIIb. In a similar manner,
so-called “AbDeg” (antibodies that promote degradation of
IgG) which are designed to bind with high affinity to FcRn
have been shown to out-compete native IgG to allow for
accelerated catabolism [107].
Other methods of interrupting FcRn and IgG interactions
include small molecule or peptide inhibitors. Peptide
inhibitors of FcRn–IgG interactions (e.g., Syntonix,
SYN1436) have been found to be effective in reduction of
IgG in cynomolgus monkeys by 80% without affecting the
concentration of albumin [110]. Dimerization of the peptide
increases the activity 200-fold compared to that of mono-
mers [111, 112]. Although inhibition of β2m function with
specific antibody can also reduce FcRn function, there may
be unwanted side effects of inhibiting other β2m-associated
molecules, such as MHC class I, CD1, and HFE [113].
Since FcRn is known to transport IgG across mucosal
epithelia, Fc-conjugated therapeutics have been shown to
reach the circulation from the lumen via transcytosis across
the intestinal or pulmonary mucosa. Various proteins, such
as erythropoietin (Epo), follicle-stimulating hormone,
interferon-alpha and -beta, have been conjugated to the Fc
region of human IgG1 to facilitate such drug delivery upon
inhalation through the upper airway where FcRn resides in
humans and non-human primates [81]. Fc fusion “mono-
mers”, which consist of Fc dimers with a monomeric
therapeutic protein that replaces the Fab region, are found
to have improved transport efficiency and longer half-life
than Fc fusion dimers [81]. Fc fusion proteins of molecular
weight ≥100 kDa can be administered in liquid aerosols
wherein they are able to cross the pulmonary epithelium by
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circulation in an FcRn-dependent pathway [79]. When
examined using an Epo-Fc monomer, the inhalation route
results in 30–60% bioavailability in non-human primates,
which is similar to that of subcutaneous injection of the
standard erythropoietin protein.
Published studies have used newborn rats to demonstrate
intestinal transport of FSH-Fc fusion proteins together with
a long half-life of circulation that approaches approximately
60 h [114]. So far, the use of intestinal mucosa for the
transport of Fc fusion proteins has yet to be rigorously
investigated.
Given the utility of such IgG-based therapeutics, simpler
strategies have been sought for the generation of such
fusion proteins. The development of cows that contain a
human IgG transgene to produce human IgG suggests that
such strategies can represent an alternative way to create large
quantities of Fc-based therapeutics protein generation [23].
Albumin-Based Therapeutics
The use of albumin to extend the half-life of therapeutic
proteins began prior to the knowledge that FcRn is critical
to albumin homeostasis. Three decades ago, chemical
conjugation of “high molecular weight carriers”, such as
albumin to methotrexate was found to be effective in half-
life extension, for example [115]. The clinical efficacy of
albumin–methotrexate in subsequent treatment of renal
carcinomas and rheumatoid arthritis was also attributed to
the increased uptake of albumin as an energy source in the
setting of inflammation and malignancy [116, 117].
Recombinant technology has now allowed for fusion of
albumin to either the carboxy or amino terminus of a
therapeutic protein of interest. Some examples include
interferon-alpha 2b (Albinterferon), granulocyte colony
stimulating factor (Albugranin), growth hormone (Albutro-
pin), insulin (albudin), CD4, hirudin, and IgG fragments
themselves [118]. Albinterferon (used for the treatment of
chronic hepatitis C), for example, can be administered less
frequently and with similar clinical efficacy as interferon
conjugated to polyethylene glycol [119]. Since both FcRn
and hepatitis C virus resides in the hepatocyte, it is
unknown whether albumin conjugation also provides the
additional benefit of targeting the liver. Furthermore, it is
unknown whether its potential side effects may be also be
related to FcRn expression in other organs such as the lung.
Albumin-based nanoparticles, such as Abrexane (albumin-
encapsulated Paclitaxel), used for the treatment of metastatic
breast cancer, were developed as a delivery vehicle to avoid
chemical solvents like Cremophor. It is unknown how this
interactswithFcRnandwhetherthesideeffectsare associated
with FcRn biology.
Other recent novel therapeutic designs have used indirect
methods to bind to albumin. Insulin detemir (Levemir,
Novo Nordisk) is an insulin analogue with a lysine residue
bound to a fatty acid (myristic acid) which will bind to
albumin in blood and later dissociate from the complex.
Drug Affinity Complex (DAC™) is a design that couples
medications to a maleimide group, which will bind specifi-
cally and irreversible to albumin [120]. The albumin-binding
domain from Streptococcus strain G148 protein G has also
been fused to a divalent anti-HER2 affibody and anti-CEA
single-chain diabodies to extend half-life [121, 122].
Conclusion
Our understanding of antibody transport and immunity has
expanded dramatically since the experimental era of Brambell
subsequent to the cloning and crystallographic resolution of
FcRn structure and the generation of experimental tools such
as Fc-deficient mice. We have clarified the observations and
predictionsmadebyBrambelldecadesago.Assummarizedin
this review, these insights have lead and are rapidly leading to
variety of enhanced therapeutics and therapeutic approaches
which co-opt these new biological principles.
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